Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.70 |
| ▸ | FDPS | P14324 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 3/20 | 0.58 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA7 | P43166 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.54 |
| ▸ | TYR | P14679 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30290009 | 1.00 | EPHX2 (0.70) | EPHX2FDPSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4176324 | 0.88 | RECQL (0.68) | EPHX2FDPSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4176326 | 0.88 | RECQL (0.68) | EPHX2FDPSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL731054 | 0.86 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2GAAAPP | |
| SCHEMBL731055 | 0.86 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2GAAAPP | |
| SCHEMBL30853135 | 0.86 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2GAAAPP | |
| SCHEMBL17301814 | 0.85 | MAOB (0.73) | EPHX2FDPSTTRNFE2L2CA12 | |
| Methyl Cis-3,4-Dimethoxycinnamate SCHEMBL2411955 | 0.85 | FDPS (0.80) | EPHX2FDPSKDM4EALDH1A1SMN1; SMN2 | |
| Methyl Cis-3,4-Dimethoxycinnamate SCHEMBL2411956 | 0.85 | FDPS (0.80) | EPHX2FDPSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1204566 | 0.83 | EPHX2 (0.72) | EPHX2FDPSKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603349-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2023-03-14 | — | — | US | disclosed |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-11014873-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD. (AU) | 2021-05-25 | — | — | US | disclosed |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-02-20 | — | — | US | disclosed |
| WO-2018144620-A9 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD. (AU) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018144620-A9 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD. (AU) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018144620-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144620-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603349-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, TGFB2 | EPHX2 2366/4885FDPS 629/4885KDM4E 4055/4885 |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, TGFB2 | EPHX2 2366/4885FDPS 629/4885KDM4E 4055/4885 |
| US-11014873-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, SMAD2 | EPHX2 2478/4885FDPS 605/4885KDM4E 4041/4885 |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, SMAD2 | EPHX2 2320/4885FDPS 970/4885KDM4E 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.